cd3 pe cy7 Search Results


cd3 pe-cyanine 7 (pe-cy 7) sk7  (Becton Dickinson)
90
Becton Dickinson cd3 pe-cyanine 7 (pe-cy 7) sk7
Cross-sectional analysis of T-cell counts and counts of seven subpopulations of CD4+ T-cells stratified by treatment (GAD65-alum (Diamyd)/placebo) presented as boxplots at study follow-up visits 0, 2, 4, 6, 8, and 10. Children treated with GAD65-alum had statistically significantly lower cell counts of (a) <t>CD3+</t> T-cells at visits 8 and 10, (b) <t>CD3</t> + CD4+ T-helper cells at visits 8 and 10, (c) CD4 + CD45RA + CD45RO-naïve T-helper cells at visit 8, (d) CD4+ CD45RA+ CD45RO+ double positive intermediate T-helper cells at visit 8, (e) CD4 + CD45RA + CD62L+ naïve T-helper cells at visit 8, (f) CD4 + CD45RA + CD62L-terminally differentiated effector memory T-helper cells at visit 8, (g) CD4 + CD62L-effector memory T-helper cells at visit 8, and (h) CD4 + CD62L+ naïve T-helper cells at visit 8 compared to the placebo group. The estimates, 95% confidence intervals, and p values for these results are provided in the figure, and complete results are presented in the Supplementary Table .
Cd3 Pe Cyanine 7 (Pe Cy 7) Sk7, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd3 pe-cyanine 7 (pe-cy 7) sk7/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cd3 pe-cyanine 7 (pe-cy 7) sk7 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
pe-cy™7 rat anti-mouse cd3  (Becton Dickinson)
90
Becton Dickinson pe-cy™7 rat anti-mouse cd3
Cross-sectional analysis of T-cell counts and counts of seven subpopulations of CD4+ T-cells stratified by treatment (GAD65-alum (Diamyd)/placebo) presented as boxplots at study follow-up visits 0, 2, 4, 6, 8, and 10. Children treated with GAD65-alum had statistically significantly lower cell counts of (a) <t>CD3+</t> T-cells at visits 8 and 10, (b) <t>CD3</t> + CD4+ T-helper cells at visits 8 and 10, (c) CD4 + CD45RA + CD45RO-naïve T-helper cells at visit 8, (d) CD4+ CD45RA+ CD45RO+ double positive intermediate T-helper cells at visit 8, (e) CD4 + CD45RA + CD62L+ naïve T-helper cells at visit 8, (f) CD4 + CD45RA + CD62L-terminally differentiated effector memory T-helper cells at visit 8, (g) CD4 + CD62L-effector memory T-helper cells at visit 8, and (h) CD4 + CD62L+ naïve T-helper cells at visit 8 compared to the placebo group. The estimates, 95% confidence intervals, and p values for these results are provided in the figure, and complete results are presented in the Supplementary Table .
Pe Cy™7 Rat Anti Mouse Cd3, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe-cy™7 rat anti-mouse cd3/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
pe-cy™7 rat anti-mouse cd3 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
fivecolor (cd45-percp-cy5.5, cd19-pe-cy7, cd38fitc, cd138-apc, cd56-pe) flow cytometry  (Partec)
90
Partec fivecolor (cd45-percp-cy5.5, cd19-pe-cy7, cd38fitc, cd138-apc, cd56-pe) flow cytometry
Cross-sectional analysis of T-cell counts and counts of seven subpopulations of CD4+ T-cells stratified by treatment (GAD65-alum (Diamyd)/placebo) presented as boxplots at study follow-up visits 0, 2, 4, 6, 8, and 10. Children treated with GAD65-alum had statistically significantly lower cell counts of (a) <t>CD3+</t> T-cells at visits 8 and 10, (b) <t>CD3</t> + CD4+ T-helper cells at visits 8 and 10, (c) CD4 + CD45RA + CD45RO-naïve T-helper cells at visit 8, (d) CD4+ CD45RA+ CD45RO+ double positive intermediate T-helper cells at visit 8, (e) CD4 + CD45RA + CD62L+ naïve T-helper cells at visit 8, (f) CD4 + CD45RA + CD62L-terminally differentiated effector memory T-helper cells at visit 8, (g) CD4 + CD62L-effector memory T-helper cells at visit 8, and (h) CD4 + CD62L+ naïve T-helper cells at visit 8 compared to the placebo group. The estimates, 95% confidence intervals, and p values for these results are provided in the figure, and complete results are presented in the Supplementary Table .
Fivecolor (Cd45 Percp Cy5.5, Cd19 Pe Cy7, Cd38fitc, Cd138 Apc, Cd56 Pe) Flow Cytometry, supplied by Partec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fivecolor (cd45-percp-cy5.5, cd19-pe-cy7, cd38fitc, cd138-apc, cd56-pe) flow cytometry/product/Partec
Average 90 stars, based on 1 article reviews
fivecolor (cd45-percp-cy5.5, cd19-pe-cy7, cd38fitc, cd138-apc, cd56-pe) flow cytometry - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
cd3 epsilon antibody (145-2c11) [pe/cy7] - chimeric  (Novus Biologicals)
N/A
The CD3 epsilon Antibody (145-2C11) [PE/Cy7] - Chimeric from Novus is a CD3 epsilon antibody to CD3 epsilon. This antibody reacts with Mouse. The CD3 epsilon antibody has been validated for the following applications: Flow
   Buy from Supplier
cd3 epsilon antibody (pc3/188a) [pe/cy7]  (Novus Biologicals)
N/A
The CD3 epsilon Antibody (PC3/188A) [PE/Cy7] from Novus is a CD3 epsilon antibody to CD3 epsilon. This antibody reacts with Human, Rat, Porcine, Bovine, Chicken, Equine, Guinea Pig, Rabbit. The CD3 epsilon antibody has been
   Buy from Supplier
cd3 epsilon antibody (tr66) [pe/cy7]  (Novus Biologicals)
N/A
The CD3 epsilon Antibody (TR66) [PE/Cy7] from Novus is a CD3 epsilon antibody to CD3 epsilon. This antibody reacts with Human. The CD3 epsilon antibody has been validated for the following applications: Flow Cytometry, Immunocytochemistry/
   Buy from Supplier
cd3 zeta [p tyr111] antibody (em-55) [pe/cy7]  (Novus Biologicals)
N/A
The CD3 zeta [p Tyr111] Antibody (EM-55) [PE/Cy7] from Novus is a CD3 zeta antibody to CD3 zeta. This antibody reacts with Human, Mouse. The CD3 zeta antibody has been validated for the following applications:
   Buy from Supplier
cd3 epsilon antibody (c3e/1308) [pe/cy7]  (Novus Biologicals)
N/A
The CD3 epsilon Antibody (C3e/1308) [PE/Cy7] from Novus is a CD3 epsilon antibody to CD3 epsilon. This antibody reacts with Human, Mouse. The CD3 epsilon antibody has been validated for the following applications: Western Blot,
   Buy from Supplier
cd3 epsilon antibody (ppt3) [pe/cy7]  (Novus Biologicals)
N/A
The CD3 epsilon Antibody (PPT3) [PE/Cy7] from Novus is a CD3 epsilon antibody to CD3 epsilon. This antibody reacts with Porcine. The CD3 epsilon antibody has been validated for the following applications: Flow Cytometry.
   Buy from Supplier
cd3 epsilon antibody (500a2) [pe/cy7]  (Novus Biologicals)
N/A
The CD3 epsilon Antibody (500A2) [PE/Cy7] from Novus is a CD3 epsilon antibody to CD3 epsilon. This antibody reacts with Mouse. The CD3 epsilon antibody has been validated for the following applications: Flow Cytometry.
   Buy from Supplier
anti-human cd3 cd3e monoclonal antibody pe-cy7 conjugated, flow validated  (Boster Bio)
N/A
Boster Bio Anti-Human CD3 CD3E Monoclonal Antibody PE-Cy7 Conjugated, Flow Validated (Catalog# FC02675-PE-Cy7). Tested in Flow Cytometry application(s). This antibody reacts with Human.
   Buy from Supplier
cd3 zeta antibody (h146-968) [pe/cy7]  (Novus Biologicals)
N/A
The CD3 zeta Antibody (H146-968) [PE/Cy7] from Novus is a CD3 zeta antibody to CD3 zeta. This antibody reacts with Human, Mouse. The CD3 zeta antibody has been validated for the following applications: Flow Cytometry.
   Buy from Supplier

Image Search Results


Cross-sectional analysis of T-cell counts and counts of seven subpopulations of CD4+ T-cells stratified by treatment (GAD65-alum (Diamyd)/placebo) presented as boxplots at study follow-up visits 0, 2, 4, 6, 8, and 10. Children treated with GAD65-alum had statistically significantly lower cell counts of (a) CD3+ T-cells at visits 8 and 10, (b) CD3 + CD4+ T-helper cells at visits 8 and 10, (c) CD4 + CD45RA + CD45RO-naïve T-helper cells at visit 8, (d) CD4+ CD45RA+ CD45RO+ double positive intermediate T-helper cells at visit 8, (e) CD4 + CD45RA + CD62L+ naïve T-helper cells at visit 8, (f) CD4 + CD45RA + CD62L-terminally differentiated effector memory T-helper cells at visit 8, (g) CD4 + CD62L-effector memory T-helper cells at visit 8, and (h) CD4 + CD62L+ naïve T-helper cells at visit 8 compared to the placebo group. The estimates, 95% confidence intervals, and p values for these results are provided in the figure, and complete results are presented in the Supplementary Table .

Journal: Journal of Immunology Research

Article Title: Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies

doi: 10.1155/2022/3532685

Figure Lengend Snippet: Cross-sectional analysis of T-cell counts and counts of seven subpopulations of CD4+ T-cells stratified by treatment (GAD65-alum (Diamyd)/placebo) presented as boxplots at study follow-up visits 0, 2, 4, 6, 8, and 10. Children treated with GAD65-alum had statistically significantly lower cell counts of (a) CD3+ T-cells at visits 8 and 10, (b) CD3 + CD4+ T-helper cells at visits 8 and 10, (c) CD4 + CD45RA + CD45RO-naïve T-helper cells at visit 8, (d) CD4+ CD45RA+ CD45RO+ double positive intermediate T-helper cells at visit 8, (e) CD4 + CD45RA + CD62L+ naïve T-helper cells at visit 8, (f) CD4 + CD45RA + CD62L-terminally differentiated effector memory T-helper cells at visit 8, (g) CD4 + CD62L-effector memory T-helper cells at visit 8, and (h) CD4 + CD62L+ naïve T-helper cells at visit 8 compared to the placebo group. The estimates, 95% confidence intervals, and p values for these results are provided in the figure, and complete results are presented in the Supplementary Table .

Article Snippet: For the CytoFLEX, cells were immunostained with CD3 PE-Cyanine 7 (PE-CY 7) (clone SK7), CD4 APC-R700 (clone RPA-T4), CD8 APC-H7 (clone SK1), CD45RA Brilliant™ Blue 515 (BB515) (clone HI100), CD45RO PerCP-CY5.5 (clone UCHL1), CD62L APC (clone DREG56), CD56 PE (clone B159), and CD16 APC (clone B73.1) all purchased from BD Biosciences.

Techniques:

Cross-sectional analysis of counts of five subpopulations of CD8+ cytotoxic T-cell stratified by treatment (GAD65-alum (Diamyd)/placebo) presented using boxplots at study follow-up visits 0, 2, 4, 6, 8, and 10. Children treated with GAD65-alum had statistically significantly lower cell counts of (a) CD3 + CD8+ cytotoxic T-cells at visits 8 and 10, (b) CD8 + CD45RA + CD45RO-naïve cytotoxic T-cells at visits 8 and 10, (c) CD8 + CD45RA + CD62L+ naïve cytotoxic T-cells at visits 8 and 10, (d) CD8 + CD62L+ naïve cytotoxic T-cells at visit 10, and (e) CD8 + CD62L-effector memory cytotoxic T-cells at visit 8 compared to the placebo group. The estimates, 95% confidence intervals, and p values for these results are provided in the figure, and complete results are presented in the Supplementary Table .

Journal: Journal of Immunology Research

Article Title: Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies

doi: 10.1155/2022/3532685

Figure Lengend Snippet: Cross-sectional analysis of counts of five subpopulations of CD8+ cytotoxic T-cell stratified by treatment (GAD65-alum (Diamyd)/placebo) presented using boxplots at study follow-up visits 0, 2, 4, 6, 8, and 10. Children treated with GAD65-alum had statistically significantly lower cell counts of (a) CD3 + CD8+ cytotoxic T-cells at visits 8 and 10, (b) CD8 + CD45RA + CD45RO-naïve cytotoxic T-cells at visits 8 and 10, (c) CD8 + CD45RA + CD62L+ naïve cytotoxic T-cells at visits 8 and 10, (d) CD8 + CD62L+ naïve cytotoxic T-cells at visit 10, and (e) CD8 + CD62L-effector memory cytotoxic T-cells at visit 8 compared to the placebo group. The estimates, 95% confidence intervals, and p values for these results are provided in the figure, and complete results are presented in the Supplementary Table .

Article Snippet: For the CytoFLEX, cells were immunostained with CD3 PE-Cyanine 7 (PE-CY 7) (clone SK7), CD4 APC-R700 (clone RPA-T4), CD8 APC-H7 (clone SK1), CD45RA Brilliant™ Blue 515 (BB515) (clone HI100), CD45RO PerCP-CY5.5 (clone UCHL1), CD62L APC (clone DREG56), CD56 PE (clone B159), and CD16 APC (clone B73.1) all purchased from BD Biosciences.

Techniques:

Cross-sectional analysis stratified by treatment (GAD-alum/placebo) evaluating whether GAD-alum treatment is associated with different T-cell subpopulations during study follow-up.

Journal: Journal of Immunology Research

Article Title: Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies

doi: 10.1155/2022/3532685

Figure Lengend Snippet: Cross-sectional analysis stratified by treatment (GAD-alum/placebo) evaluating whether GAD-alum treatment is associated with different T-cell subpopulations during study follow-up.

Article Snippet: For the CytoFLEX, cells were immunostained with CD3 PE-Cyanine 7 (PE-CY 7) (clone SK7), CD4 APC-R700 (clone RPA-T4), CD8 APC-H7 (clone SK1), CD45RA Brilliant™ Blue 515 (BB515) (clone HI100), CD45RO PerCP-CY5.5 (clone UCHL1), CD62L APC (clone DREG56), CD56 PE (clone B159), and CD16 APC (clone B73.1) all purchased from BD Biosciences.

Techniques: